SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Clinical Research Organizations-CROs
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RWReeves who wrote (20)1/24/2000 6:26:00 PM
From: RWReeves  Read Replies (1) of 46
 
QTRN breaks out today with a bid for the mid 30's only to fall back to 27 in general market ugliness. What me worry?

Nevertheless,

<QTRN, another chance at the 18-19 price. Patience with this one.> was posted 12/23 and it is up nearly 100% if you sold off on the spike as I did.

...And bought KNDL, which I think has lots better leverage than QTRN and some CVD. If the CRO's have now come to the attention of The Street as "tools" companies, not relying on FDA approval to sell, but on R&D bucks to be spent, I'd say the writing on the wall is pretty clear, eh?

This sector may never get the sex appeal of genomics ( well PPDI might, VTIV is pure uncut corporate pharma and CVGR, well, read the filings for an interesting saga. But actually these pups have some (IMO) better near term earnings outlook. When momo abandons you and your broker calls about those nasty margin requirements in the handbook, these are worth remembering.

QTRN calls this morning were not too expensive either.

RWR
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News